Artificial Intelligence-enabled Management of Atrial Fibrillation(ABLE-AF Trial)

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1006 participants.

Also called NCT07938281

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose diagnostic
Phase
Not applicable
Enrolled
  • 1,006 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07938281
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07938281. Randomized; double masking; primary purpose diagnostic. Start 2026-12-01 (anticipated); primary completion 2029-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Artificial Intelligence-enabled Management of Atrial Fibrillation(ABLE-AF Trial)
Condition
AF - Atrial Fibrillation
Intervention (Device)
ECG Analysis Software AiTiALVDD
Intervention (Device)
ECG Analysis Software AiTiALVSD
Lead sponsor
Korea University Anam Hospital (class: other)

Record details

Record id
cardio:ct-nct07938281
Content hash
bc0674e00b45e1bd0c9959f9ce9caa5d50d8f70a6edb6d76d45688b46513bcc9